EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapy with Fucosylated Chondroitin Sulfate Extracted from Holothuria grisea in Allergic Airway Inflammation Model

Mayck Medeiros, Juliana Maria Motta, Cassia Lisboa Braga, Monique Martins Melo, Patricia Rieken, Macedo Rocco, Mauro Sérgio Gonçalves Pavão, Pedro Leme Silva, Fernanda Ferreira Cruz

Inflammopharmacology · 05.11.2026

DOI: 10.1007/s10787-026-02439-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, online erschienen am 05.11.2026. Verfasst von Mayck Medeiros und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current therapies for asthma are limited by significant adverse effects, and many patients with severe asthma are still unable to achieve adequate symptom control, highlighting the need for novel therapeutic strategies. Fucosylated chondroitin sulfate (FucCS), a glycosaminoglycan isolated from the sea cucumber Holothuria grisea , demonstrates anti-inflammatory properties. This study investigated the therapeutic potential of FucCS in a murine model of ovalbumin (OVA)-induced allergic airway inflammation. C57BL/6 mice were sensitized and challenged with OVA and then treated intraperitoneally with FucCS (2 mg/kg), dexamethasone (DEXA, 2 mg/kg, positive control), or saline (SAL, vehicle control). Additional control mice received saline (CTRL/SAL) instead of OVA during both sensitization and challenge. Pulmonary function, the extent of peribronchial inflammation, total and differential cell counts in bronchoalveolar lavage fluid (BALF) and lung tissue, as well as levels of key inflammatory mediators were assessed. Compared to the OVA/SAL group, treatment with FucCS significantly reduced basal airway resistance, peribronchial inflammation, and polymorphonuclear cell infiltration in lung parenchyma. Furthermore, FucCS therapy attenuated BALF total cellularity and interleukin (IL)-4 levels and reduced IL-5 levels in lung homogenates, with effects comparable to dexamethasone. Neither treatment altered BALF eosinophil percentage. These findings demonstrate a limited, but significant anti-inflammatory effects of FucCS in experimental allergic inflammation and support its further development as a therapeutic candidate.

Schlagwörter

Stichwörter der Autor:innen

anti-inflammatory therapyasthmaeosinophilglycoconjugatesmarine drugs

Autor:innen und Institutionen

  • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Rio de Janeiro, Brazil.
  • Laboratory of Connective Tissue, Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Laboratory of Biochemistry and Cell Biology of Glycoconjugates, Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. ffcruz@biof.ufrj.br.
  • National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Rio de Janeiro, Brazil. ffcruz@biof.ufrj.br.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Universidade Federal Do Rio De Janeiro
  • National Institute of Science and Technology for Regenerative Medicine

Zitieren

APA

Medeiros, M., Motta, J. M., Braga, C. L., Melo, M. M., Rieken, P., Rocco, M., Pavão, M. S. G., Silva, P. L., & Cruz, F. F. (2026). Therapy with Fucosylated Chondroitin Sulfate Extracted from Holothuria grisea in Allergic Airway Inflammation Model. Inflammopharmacology. https://doi.org/10.1007/s10787-026-02439-4

Vancouver

Medeiros M, Motta JM, Braga CL, Melo MM, Rieken P, Rocco M, et al. Therapy with Fucosylated Chondroitin Sulfate Extracted from Holothuria grisea in Allergic Airway Inflammation Model. Inflammopharmacology. 2026. doi:10.1007/s10787-026-02439-4

BibTeX
@article{Medeiros2026,
  author = {Medeiros, Mayck and Motta, Juliana Maria and Braga, Cassia Lisboa and Melo, Monique Martins and Rieken, Patricia and Rocco, Macedo and Pavão, Mauro Sérgio Gonçalves and Silva, Pedro Leme and Cruz, Fernanda Ferreira},
  title = {Therapy with Fucosylated Chondroitin Sulfate Extracted from Holothuria grisea in Allergic Airway Inflammation Model},
  journal = {Inflammopharmacology},
  year = {2026},
  doi = {10.1007/s10787-026-02439-4}
}
Kostenlos starten →